Source: Annual Congress 2009 - Translational research/biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. H. Chou, Y. W. Chen (Kaohsiung, Taiwan). Prediction of efficacy of inhaled steroid on COPD by alveolar-capillary membrane permeability. Eur Respir J 2009; 34: Suppl. 53, 2925

Member's Comments

No comment yet.

Related content which might interest you: Effect of inhaled salt-bromide-iodine thermal water on airway inflammation in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004 Evaluation of alveolar-capillary permeability of lung cancer patients Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008 Inhaled furosemide & lung epithelial permeability: an added dimension to asthma therapy Source: Eur Respir J 2001; 18: Suppl. 33, 424s Year: 2001 The effect of inhaled corticosteroids on airway Na/K ATPase content in patients with asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Altered composition of airway basement membranes in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019 Year: 2019 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017 Protective effects of salmeterol on impeded alveolar-capillary gas transfer with saline infusion in COPD patients: preliminary results Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 The lung microbiota changes associated with inhaled corticosteroid and azithromycin in murine model of COPD Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation Source: Eur Respir J, 54 (3) 1901088; 10.1183/13993003.01088-2019 Year: 2019 Refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation: is this phenomenon airway remodeling? Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011 Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Airway inflammation and inhaled corticosteroids in COPD Source: Eur Respir J, 49 (6) 1700289; 10.1183/13993003.00289-2017 Year: 2017 Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Source: Eur Respir J 2006; 27: 172-187 Year: 2006 Effect of add-on montelukast to inhaled corticosteroids on excessive airway narrowing in adult asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Effects of inhaled corticosteroids on asthmatic inflammation: The FeNOtype trial Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012